Cephalon is one of the world’s fastest growing biopharmaceutical companies, currently marketing more than twenty products internationally in the field of central nervous system, pain and oncology.

Cephalon employs more than 3,000 people of which 1,000 are in Europe, with major offices in France, Germany, Italy, Spain and the United Kingdom as well as offices in Ireland, the Benelux, Poland and Scandinavia.

Cephalon reinvests almost thirty percent of its sales revenues in R&D. This investment is crucial to building a balanced pipeline of new chemical entities and product enhancements. From researching target molecules to advancing late-stage compounds, Cephalon is contributing to scientific understanding whilst preparing a new portfolio of therapies that promises to have a profound impact on human health.

Cephalon’s R&D initiatives focus heavily on oncology, pain and the central nervous system. With vast experience and expertise in molecular biology and behavioural pharmacology, biochemistry, cell biology, tumour biology and chemistry, Cephalon is dedicated to the development of new medicines and to building product franchises in this area.